INNOVIVA, INC. Payments for Repurchase of Common Stock
Shares the company repurchased and the cash it paid, as filed in its 10-Q and 10-K XBRL (statement of shareholders' equity and cash flow statement).
- INNOVIVA, INC. payments for repurchase of common stock for the quarter ending 2026-06-30 was $31.07M.
- INNOVIVA, INC. payments for repurchase of common stock for the quarter ending 2026-03-31 was $20.25M.
- INNOVIVA, INC. payments for repurchase of common stock for the quarter ending 2025-12-31 was $4.53M.
- INNOVIVA, INC. payments for repurchase of common stock for the quarter ending 2025-09-30 was $0.00.
- INNOVIVA, INC. payments for repurchase of common stock for fiscal 2025 was $4.53M, a 69.33% decline from fiscal 2024.
- INNOVIVA, INC. payments for repurchase of common stock for fiscal 2024 was $14.78M, a 80.49% decline from fiscal 2023.
- INNOVIVA, INC. payments for repurchase of common stock for fiscal 2023 was $75.73M, a 790.60% increase from fiscal 2022.
- INNOVIVA, INC. payments for repurchase of common stock for fiscal 2022 was $8.50M, a 97.84% decline from fiscal 2021.
| Period end | Payments for Repurchase of Common Stock 3 month | Payments for Repurchase of Common Stock 12 month |
|---|---|---|
| 2026-06-30 | $31.07M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $55.85M derived: sum of 4 quarters · filed 2026-08-05 |
| 2026-03-31 | $20.25M 10-Q · filed 2026-05-06 | $24.78M derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-12-31 | $4.53M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $4.53M 10-K · filed 2026-02-25 |
| 2025-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-05 | $0.00 derived: sum of 4 quarters · filed 2026-08-05 |
| 2025-03-31 | $0.00 10-Q · filed 2026-05-06 | $5.21M derived: sum of 4 quarters · filed 2026-05-06 |
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $14.78M 10-K · filed 2026-02-25 |
| 2024-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $29.41M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-06-30 | $5.21M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | $40.48M derived: sum of 4 quarters · filed 2026-02-25 |
| 2024-03-31 | $9.57M 10-Q · filed 2025-05-07 | $44.56M derived: sum of 4 quarters · filed 2026-02-25 |
| 2023-12-31 | $14.64M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-25 | $75.73M 10-K · filed 2026-02-25 |
| 2023-09-30 | $11.07M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $69.59M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $9.29M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-07-31 | $58.52M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $40.73M 10-Q · filed 2024-05-08 | $49.24M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $8.50M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $8.50M 10-K · filed 2025-02-26 |
| 2022-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-01 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-02 | $0.00 derived: sum of 4 quarters · filed 2024-03-05 |
| 2022-03-31 | $0.00 10-Q · filed 2023-05-09 | |
| 2021-12-31 | $0.00 derived: 10-K/A 12 month − 10-Q 9 month · filed 2024-03-05 | $394.15M 10-K/A · filed 2024-03-05 |
| 2021-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | |
| 2020-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-28 | $0.00 10-K · filed 2023-02-28 |
| 2020-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2021-10-27 | |
| 2019-12-31 | $0.00 10-K/A · filed 2022-03-17 | |
| 2018-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $0.00 10-K · filed 2020-02-19 |
| 2017-12-31 | $80.00M derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-19 | $97.50M 10-K · filed 2020-02-19 |
| 2017-09-30 | $17.50M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-10-31 | $30.03M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $33.76M derived: sum of 4 quarters · filed 2019-02-19 |
| 2017-03-31 | $0.00 10-Q · filed 2017-05-05 | $52.74M derived: sum of 4 quarters · filed 2019-02-19 |
| 2016-12-31 | $12.53M derived: 10-K 12 month − 10-Q 9 month · filed 2019-02-19 | $78.09M 10-K · filed 2019-02-19 |
| 2016-09-30 | $21.23M derived: 10-Q 9 month − 10-Q 6 month · filed 2017-11-03 | $91.20M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-06-30 | $18.97M derived: 10-Q 6 month − 10-Q 3 month · filed 2017-08-08 | $69.97M derived: sum of 4 quarters · filed 2018-02-23 |
| 2016-03-31 | $25.36M 10-Q · filed 2017-05-05 | $50.99M derived: sum of 4 quarters · filed 2018-02-23 |
| 2015-12-31 | $25.64M derived: 10-K 12 month − 10-Q 9 month · filed 2018-02-23 | $25.64M 10-K · filed 2018-02-23 |
| 2015-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2016-11-03 | |
| 2015-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2016-08-04 | |
| 2015-03-31 | $0.00 10-Q · filed 2016-05-05 | |
| 2014-12-31 | $0.00 10-K · filed 2017-02-28 | |
| 2013-12-31 | $0.00 10-K · filed 2016-02-24 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| ANAPTYSBIO, INC (ANAB) | United States | $1.546B | -60.20 |
| Kailera Therapeutics, Inc. (KLRA) | United States | $1.552B | |
| Syndax Pharmaceuticals Inc (SNDX) | United States | $1.606B | -8.82 |
| Oric Pharmaceuticals, Inc. (ORIC) | United States | $1.367B | -8.00 |
| Rapport Therapeutics, Inc. (RAPP) | United States | $1.623B | -14.56 |
| Stoke Therapeutics, Inc. (STOK) | United States | $1.630B | -9.82 |
| Xeris Biopharma Holdings, Inc. (XERS) | United States | $1.632B | -80.10 |